Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria …
Previously vaccinated children from 12 months of age, adolescents and adults NimenrixTM may be given as a booster dose to individuals who have previously received primary vaccination …
2014年4月4日 · Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the …
Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria …
In June 2012, the FDA approved a combination vaccine against two types of meningococcal disease and Hib disease for infants and children 6 weeks to 18 months old. The vaccine, …
NIMENRIX®: 1 dose given as 0.5 mL . IM. G. A MENVEO ® and NIMENRIX® are indicated for children 2-23 months of age. MENVEO®, MENACTRA® or NIMENRIX® vaccine may be used …
Nimenrix is a conjugate vaccine that helps to provide protection against invasive disease caused by the bacteria Neisseria meningitidis types A, C, W-135 and Y. Invasive disease occurs when …
NIMENRIX (meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine) Product Information. Product Monograph (download PDF, 429KB) Patient Information (download PDF, …
Nimenrix is a meningococcal conjugate vaccine to protect against meningococcal groups A, C, W and Y. From 1 July 2024, Nimenrix will be funded for eligible tamariki under 12 months of age …
What NIMENRIX is used for NIMENRIX is a vaccine used to help prevent meningococcal disease, caused by four types of Neisseria meningitidis bacteria (types A, C, W and Y). NIMENRIX …